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rehabilitation in 1997. Treatment episodes required a 30
day depression and alcoholism diagnosis-free period. Use
of medications and therapy was examined in the year
after the index diagnosis. Healthcare costs, utilization,
and suicide diagnosis were examined in patients with
depression and alcoholism and patients with depression
alone in the two years after the diagnosis. RESULTS: The
1-year prevalence rate of depression, alcoholism, and
depression with alcoholism in 2000 was: 40 per 1000, 2
per 1000, and 1 per 1000. The percent of persons with
depression and alcoholism receiving psychotherapy, 
alcoholism rehabilitation, alcoholism detoxiﬁcation, 
alcoholism medications, or antidepressant mediations
was 58%, 2%, 3%, 24%, and 79%, respectively. Persons
with depression and alcoholism had much higher outpa-
tient, inpatient, and pharmaceutical mental health and
substance abuse and total costs than persons with depres-
sion alone. Persons with depression and alcoholism had
much higher rates of suicide (11% versus 0.5) and emer-
gency room admissions than persons with depression
alone. CONCLUSION: Providers need to better identify
persons with comorbid alcoholism and depression and
more effective treatment needs to be developed and imple-
mented.
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OBJECTIVE: To examine healthcare utilization for
patients receiving atypical and typical antipsychotic med-
ications. METHODS: This was a retrospective, observa-
tional cohort analysis of a pharmacy and medical claims
database from a southeastern US health plan. The phar-
macy claims of subjects between the ages of 6 and 65
years were retrospectively identiﬁed from the health plan
database. Inclusion criteria included the initiation of a
single antipsychotic agent between July 1, 1999 and Sep-
tember 30, 2000; no antipsychotic medication usage 180
days prior to the index prescription date; and continuous
health plan enrollment for a 6-month period before and
12-month period after the index prescription date. Neg-
ative binomial regression was utilized to compare: 1)
ofﬁce-based outpatient utilization; 2) hospital-based out-
patient utilization; 3) inpatient admission; and 4) emer-
gency room utilization. RESULTS: A total of 469 patients
met initial study criteria. Atypical and typical antipsy-
chotics were prescribed to 384 and 85 patients, respec-
tively. Mean length of therapy (days) for the atypical
cohort was signiﬁcantly longer (136 vs. 80; p < 0.001).
The atypical cohort was signiﬁcantly more adherent to
therapy than the typical cohort (mean medication pos-
session ratio (MPR) = 0.53 vs. 0.24; p < 0.001). After
adjusting for differences in demographics, baseline uti-
lization, MPR, and length of therapy, (atypical N = 305,
typical N = 72), the atypical cohort experienced signiﬁ-
cantly fewer ofﬁce visits (2635 vs. 4249 per 1000 patients
per month [P1000PPM]; p = 0.005), signiﬁcantly fewer
inpatient admissions (197 vs. 511 P1000PPM; p = 0.032),
and signiﬁcantly fewer emergency room visits (124 vs.
354 P1000PPM; p = 0.002). Differences in hospital 
outpatient visits were not statistically signiﬁcant (307 vs.
634 P1000PPM; p > 0.05). CONCLUSIONS: Atypical
antipsychotic users were more adherent and remained 
on therapy longer. In addition, patients using atypical
antipsychotic agents were shown to have lower rates of
healthcare resource utilization. This study conﬁrms
thoughts that there is a relationship between adherence
to medication and use of healthcare resources.
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OBJECTIVES: Depression and weight loss are common
problems in older nursing facility (NF) residents. 
Mirtazapine is among the interventions clinicians use to
prevent weight loss in depressed, frail elderly because it
has been reported to be associated with weight gain. Nev-
ertheless, limited data in weight outcomes of depressed
NF residents are available. Our objective was to examine
changes in weight associated with the use of mirtazapine
compared to other non-TCA antidepressant therapies in
the NF population. METHODS: A retrospective chart
review was conducted for 189 NF residents with new
single-antidepressant treatment regimens with at least 6
months of post-treatment weight data. OLS regression
was performed to assess weight change and percentage
weight change at three months and six months. Mirtaza-
pine-treated subjects served as the controlled group (n =
27). Other factors affecting weight were included as
explanatory variables, such as gender, age, co-morbidi-
ties, baseline weight and relative therapeutic dose.
RESULTS: We found no statistical signiﬁcant differences
in weight change at three months and at six months
between mirtazapine and all non-TCA antidepressants
except ﬂuoxetine which was associated with a gain of
four pounds relative to mirtazapine at three months (p =
0.0482). A hypertension diagnosis was associated with
signiﬁcant weight gains at 3 months (2.2 lbs., p = 0.0439
or +1.7%, p = 0.0361) and at 6 months (3.99 lbs., p =
0.0051 or +3.1%, p = 0.0048). A diagnosis of diabetes
was associated with weight loss at 6 month (-3.6 lbs., p
= 0.0370; -3.1%, p = 0.0187). Baseline weight was asso-
ciated with increased weight loss in women at 6 months
(-0.089 lb (per pound baseline), p = 0.0388). CONCLU-
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SIONS: With the exception of ﬂuoxetine, our sample of
NF residents showed that weight gains with mirtazapine
were not statistically different from other non-TCA 
antidepressants once factors such as baseline weight,
gender, dose and co-morbid diagnoses are controlled for 
statistically.
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OBJECTIVE: To evaluate the effectiveness of ﬂuoxetine
90mg every week/every 2 weeks in elderly nursing home
residents. METHOD: Twenty patients were randomly
selected who had been stabilized on 20mg ﬂuoxetine
daily for 3 months were switched to ﬂuoxetine 90mg
every week. An additional 20 patients were randomly
selected who had been stabilized on 10mg ﬂuoxetine
daily for 3 months and switched to ﬂuoxetine 90mg every
2 weeks. The Geriutric Depression Scale (GDS) was
administered to all patients to assess effectiveness one
week before and six weeks after the switch. Costs were
calculated as drug acquisition cost, nursing time, and
pharmacy time. Generic ﬂuoxetine was used in both cases
for 3 months prior to switching to ﬂuoxetine 90mg
weekly. RESULTS: Subject Characteristics: Fluoxetine
Weekly Group/Fluoxetine Every 2 Week Group Respec-
tively: Age: 81 + 8/82 + 9, Sex: 14 females/8 females, Eth-
nicity: 6% AA, 1% Hispanic/7% AA, 1% Hispanic.
Effectiveness: There was no statistically signiﬁcant differ-
ence in GDS scores before or after the switch for either
the ﬂuoxetine 90mg weekly group or the ﬂuoxetine 90
mg every 2 weeks group. Costs: Costs ($) for a 2-week
period before and after the switch were as follows: Flu-
oxetine 90mg Weekly Before/After Respectively: Drug
acquisition costs—1.68/33.38, Nursing costs—21.00/
3.00, Pharmacy costs—23.38/3.34, Total—46.06/39.72,
P > 0.05. Fluoxetine 90mg every 2 weeks Before/After
Respectively: Drug acquisition costs—0.84/16.69,
Nursing costs—21.00/1.50, Pharmacy costs—23.38/
3.34, Total—45.22/19.03, P < .05. CONCLUSION: This
suggests that ﬂuoxetine 90mg weekly and ﬂuoxetine 90
mg every 2 weeks are effective in nursing home patients.
The costs associated with the administration of medica-
tion may be a more signiﬁcant factor to consider when
evaluating cost effectiveness. Our ﬁndings are limited by
the small sample size and did not account for other costs
due to adverse effects, noncompliance, and medication
errors.
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OBJECTIVES: Atypical antipsychotic (AAP) drugs are
recommended as a ﬁrst-line pharmacotherapeutic strat-
egy for schizophrenia. Although these drugs offer an
improved neurological side-effect proﬁle, they can be
associated with important weight gain, increased serum
triglyceride levels, glucose intolerance, and diabetes 
mellitus. Clustering of these effects is associated with the
metabolic syndrome, which can greatly increase the risk
of coronary heart disease (CHD). The objective of this
study was to examine the impact of metabolic induced
changes by AAPs on the development of CHD in schizo-
phrenic patients. METHODS: A Markov model was 
constructed using disease state probabilities derived 
from published PROCAM logistic regression model and
published literature to link risk factors to disease inci-
dence in order to estimate the risk of developing CHD.
Based on the presence or absence of potential CHD risk
factors, persons were assigned transition probabilities 
of remaining in good health or moving into develop-
ing CHD (absorbing phase). The main outcome of the 
study was the risk of developing CHD in a hypothetical
cohort, and in turn, to estimate the proportion remaining
disease-free. RESULTS: The relative risk of CHD associ-
ated with triglyceride level and obesity was examined.
Clustering of these two metabolic effects, seen in patients
treated with certain AAPs, is associated with a two-fold
increased risk of CHD in men. The model generated real-
istic results, which are in total agreement with previously
published literature. CONCLUSIONS: This model can be
used as an effective instrument for assisting in the care of
persons at high risk of CHD. Moreover, it can be used to
estimate the impact of AAP induced metabolic changes
on the risk of CHD in individual patients. Physicians can
also use this tool to assess the beneﬁt/risk ratio of patients
that respond well to AAPs but develop metabolic side
effects.
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Objective: To assess recent pharmacologic treatment pat-
terns for hospitalized bipolar patients. METHODS: Using
